Dey, Ranadhir http://orcid.org/0000-0003-0069-7867
Alshaweesh, Jalal
Singh, Kamaleshwar P.
Lypaczewski, Patrick http://orcid.org/0000-0002-5550-712X
Karmakar, Subir
Klenow, Laura
Paulini, Kayla http://orcid.org/0000-0001-9379-9509
Kaviraj, Swarnendu
Kamhawi, Shaden http://orcid.org/0000-0003-4304-636X
Valenzuela, Jesus G. http://orcid.org/0000-0002-5589-9450
Singh, Sanjay
Hamano, Shinjiro http://orcid.org/0000-0003-3881-8337
Satoskar, Abhay R. http://orcid.org/0000-0001-5989-1520
Gannavaram, Sreenivas http://orcid.org/0000-0002-6557-8220
Nakhasi, Hira L. http://orcid.org/0000-0003-4941-1620
Matlashewski, Greg http://orcid.org/0000-0002-8971-5525
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
Article History
Received: 26 January 2023
Accepted: 19 October 2023
First Online: 2 November 2023
Competing interests
: The authors declare the following competing interests: The FDA is currently a co-owner of two US patents that claim attenuated Leishmania species with the Centrin gene deletion (US7,887,812 and US 8,877,213). K.P.S., Subir Karmakar, Swarnendu Kaviraj and S.S. are employees of Gennova Biopharmaceuticals. The remaining authors declare no competing interests.